Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT07646821RecruitingPhase 1/Phase 2
Study of two drugs for leukemia with TP53 mutation
This trial tests combining two drugs, ropeginterferon alfa-2b and azacitidine, for people with myelodysplastic syndrome or acute myeloid leukemia that has a TP53 gene change. The treatment may help control the cancer, and the study includes people who are newly diagnosed or whose disease has not responded to prior therapy.
Houston, TexasAges 18 years+ - NCT06782373RecruitingPhase 2
Pacritinib for VEXAS syndrome
This trial tests whether the drug pacritinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition that causes inflammation in various parts of the body. It may be a new treatment option for those who still have inflammation despite taking steroids.
Scottsdale, ArizonaAges 18 years+ - NCT07878351Recruiting
Blood test to guide treatment for large B-cell lymphoma
This study looks at whether a blood test can help doctors understand and monitor large B-cell lymphoma during treatment. It may help guide decisions about your care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT01745237Recruiting
Heart MRI to predict health outcomes
This study uses a routine heart MRI to help doctors predict how your heart condition may progress. It aims to improve future treatment decisions by looking at detailed images of your heart.
Durham, North CarolinaAges 18 years+ - NCT07877610RecruitingPhase 1/Phase 2
Engineered immune cells for leukemia that has not responded to treatment
This trial tests a new type of cell therapy for people with a fast-growing blood cancer (AML or BPDCN) that has not improved with standard treatments. The therapy uses specially modified immune cells (called CAR T cells) to target and kill cancer cells. It may be an option for those who have run out of other treatment choices.
Monza, MBAges 6 months–75 years - NCT07877727Recruiting
Rare blood disease network for better care
This study creates a national network to collect health information and samples from people with certain rare blood diseases. The goal is to improve treatment and understand these conditions better.
AvellinoAges 4 weeks–65 years - NCT07674277Recruiting
Virtual reality for pain relief in sickle cell crisis
This study tests whether using a virtual reality headset can help reduce pain for adults with sickle cell disease during a painful crisis. The trial aims to see if this non-drug approach can improve comfort while receiving IV pain medication.
Baltimore, MarylandAges 18–88 - NCT07159620RecruitingPhase 2
Combination treatment for a rare type of T-cell leukemia
This trial tests a combination of drugs for people newly diagnosed with a rare and aggressive type of T-cell acute lymphoblastic leukemia (ETP-ALL). The goal is to see if this combination can help put the leukemia into remission.
Suzhou, JiangsuAges 14–75 - NCT07722611RecruitingPhase 2/Phase 3
Bomedemstat for polycythemia vera after hydroxyurea failure
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
JerusalemAges 18 years+ - NCT00344331Recruiting
Testing blood and MRI markers for Niemann-Pick type C
This study measures biochemical (blood/biologic) markers and may use clinical evaluation and MRI to better understand Niemann-Pick disease type C. It could help improve how the condition is tracked and understood over time.
Bethesda, MarylandAges 1 day–120 years - NCT07463807RecruitingPhase 1/Phase 2
Comparing two drug combinations for multiple myeloma that returned quickly
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Duarte, CaliforniaAges 18 years+ - NCT03819803RecruitingPhase 3
Fecal transplant for gut graft-versus-host disease
This study tests whether restoring healthy gut bacteria using a fecal microbiota transplant can improve steroid-refractory gut graft-versus-host disease (aGvHD) after stem cell transplant. If your gut symptoms are your first episode and your stool bacteria diversity is low, this trial may be an option worth screening for.
Graz, StyriaAges 18–70 - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT06303193RecruitingPhase 1/Phase 2
Testing a kinase inhibitor drug for MDS and MDS/MPN in adults and teens
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
Bethesda, MarylandAges 12–120 - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Sacramento, CaliforniaAges 2 months+ - NCT07397715Recruiting
Ultrasound signs of adenomyosis and related symptoms
This study uses ultrasound to look for signs of adenomyosis (a condition where the uterine lining grows into the muscle wall) and see how those signs relate to symptoms. It may help doctors better diagnose and treat the condition.
LeuvenAges 18 years+ - NCT07437950RecruitingPhase 2
Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Coeur d'Alene, IdahoAges 60 years+ - NCT07775313Enrolling by invitationPhase 1/Phase 2
Gene therapy for WHIM syndrome
This trial tests a one-time gene therapy treatment for WHIM syndrome, a rare immune disorder. It aims to fix the genetic cause to improve your body's ability to fight infections. Your stem cells will be collected, edited in a lab, and given back to you after some chemotherapy to prepare your body.
Bethesda, MarylandAges 3–75 - NCT07683104Recruiting
How trisomy 8 autoinflammatory disease progresses over time
This study follows people who have trisomy 8 (an extra copy of a chromosome) that causes inflammation and mouth/genital ulcers, and their family members. Researchers want to learn how this condition changes over time, so they can better understand and treat it.
Bethesda, MarylandAges 1 day–99 years - NCT07162571Enrolling by invitationPhase 1/Phase 2
Engineered immune cells for advanced leukemia or lymphoma
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
MinskAges 18 years+ - NCT07333430RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory multiple myeloma
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
JerusalemAges 18 years+ - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Miami, FloridaAges 18 years+ - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.